← All trials
NCT06888817
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Apr 30, 2028
- Completion date
- Apr 30, 2030
- First posted
- Mar 21, 2025
- Last posted
- Mar 30, 2025
- Enrollment
- 408
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Netherlands Cancer InstituteLead sponsor
- Medical Center HaaglandenCollaborator
- Free University of AmsterdamCollaborator
- Netherlands Cancer InstituteOfficial
- Utrecht UniversityCollaborator
- Leiden UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.